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Abstract Clostridium difficile is a leading cause of death
from gastrointestinal infections in North America. Antibiotic
therapy is effective, but the high incidence of relapse and the
rise in hypervirulent strains warrant the search for novel treat-
ments. Surface layer proteins (SLPs) cover the entire
C. difficile bacterial surface, are composed of high-
molecular-weight (HMW) and low-molecular-weight
(LMW) subunits, and mediate adherence to host cells.
Passive and active immunization against SLPs has enhanced
hamster survival, suggesting that antibody-mediated neutrali-
zation may be an effective therapeutic strategy. Here, we iso-
lated a panel of SLP-specific single-domain antibodies
(VHHs) using an immune llama phage display library and
SLPs isolated from C. difficile hypervirulent strain QCD-
32g58 (027 ribotype) as a target antigen. Binding studies re-
vealed a number of VHHs that bound QCD-32g58 SLPs with
high affinity (KD=3–6 nM) and targeted epitopes located on
the LMW subunit of the SLP. The VHHs demonstrated
melting temperatures as high as 75 °C, and a few were resis-
tant to the gastrointestinal protease pepsin at physiologically
relevant concentrations. In addition, we demonstrated the
binding specificity of the VHHs to the major C. difficile
ribotypes by whole cell ELISA, where all VHHs were found
to bind 001 and 027 ribotypes, and a subset of antibodies were
found to be broadly cross-reactive in binding cells representa-
tive of 012, 017, 023, and 078 ribotypes. Finally, we showed
that several of the VHHs inhibited C. difficile QCD-32g58
motility in vitro. Targeting SLPs with VHHs may be a viable
therapeutic approach against C. difficile-associated disease.
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Introduction
Clostridium difficile is currently the leading hospital-acquired
infection in developed countries (Karas et al. 2010). As a
Gram-positive, anaerobic, endospore-forming gastrointestinal
(GI) pathogen, the bacterium causes C. difficile-associated
disease (CDAD) in humans and animals. Symptoms of
CDAD range from mild antibiotic-associated diarrhea to
psuedomembraneous colitis and death, with an estimated as-
sociated health care cost of $3.2 billion annually in the USA
(Dubberke and Olsen 2012; Ghantoji et al. 2010). From 2002
to 2005, the Canadian province of Québec suffered a CDAD
epidemic, largely associated with a predominant strain re-
ferred to as North American pulsed-field type 1 (NAP1),
ribotype 027, toxinotype III, and restriction endonuclease
group BI (Bourgault et al. 2006; Gilca et al. 2010; Hubert
et al. 2007; Loo et al. 2005; Pépin et al. 2004; Warny et al.
2005). These ribotype 027 strains were undetected in 2000
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and 2001 but were responsible for the Québec outbreak in
which its prevalence was estimated at 75.2 % of all polymer-
ase chain reaction (PCR)-ribotyped strains in 2003
(MacCannell et al. 2006). Québec strain QCD-32g58
(NZ_CM000287.1) is one such isolate belonging to this group.
Strains within PCR ribotype 027 have evolved to produce ele-
vated levels of toxins A and B (Dupuy et al. 2008; Warny et al.
2005), have acquired antibiotic resistance cassettes (Bourgault
et al. 2006; Pépin et al. 2005; Schmidt et al. 2007; Spigaglia
et al. 2008; Stabler et al. 2009), and have shown enhanced
sporulation ability (Åkerlund et al. 2008), all of which contrib-
ute to their virulence. Toxins A and B (TcdA and TcdB) are the
primary C. difficile virulence factors and are therapeutic targets
(Giannasca and Warny 2004; Hussack and Tanha 2010; Jank
and Aktories 2008; Jank et al. 2007); however, targeting other
virulence factors such as surface layer proteins (SLPs), cell wall
proteins, and flagellar components have also been proposed as
therapeutic strategies (Ghose 2013).
SLPs are common to almost all Archaea and can be found
in nearly every phylogenetic group within Eubacteria (Fagan
and Fairweather 2014; Sleytr and Beveridge 1999). These
proteins have been identified as virulence factors for bacteria
such as Campylobacter fetus and Aeromonas salmonicida,
providing the cells with structural integrity, acting as molecu-
lar sieves and playing a role in adherence and immune evasion
(Grogono-Thomas et al. 2000; Hamadeh et al. 1995; Sara and
Sleytr 2000).C. difficile produces unique SLPs in that they are
cleaved from a common precursor, SlpA, to generate the
HMW and LMW subunits (Calabi et al. 2001). The two sub-
units associate to form mature proteins that cover the entire
surface of the bacterium in a para-crystalline layer. The LMW
subunit is highly immunogenic (Pantosti et al. 1989), is sur-
face exposed (Fagan et al. 2009), and exhibits low inter-strain
identity among different PCR ribotypes (Calabi and
Fairweather 2002; Spigaglia et al. 2011). The high variability
observed could be due to a lack of functional constraints or the
evolutionary need to evade host immune responses. Indeed,
C. difficile SLPs play a critical role in bacterial adherence to
host cells (Calabi et al. 2002; Drudy et al. 2001; Merrigan
et al. 2013; Takumi et al. 1991) and thereby contribute to
colonization and the persistence of infection. They have also
been shown to perturb cytokine homeostasis and modulate
immune responses (Ausiello et al. 2006; Bianco et al. 2011;
Collins et al. 2014; Ryan et al. 2011). SLPs induce maturation
of dendritic cells and the subsequent generation of a T-helper
cell response through Toll-like receptor 4 (TLR4), thereby
altering host inflammatory and regulatory cytokines toward
an inflammatory state and contributing to the damage of the
intestinal epithelium. Interestingly, human patients with re-
lapsing C. difficile incidences were found to exhibit a lower
immunoglobulin M (IgM) response to SLPs compared to pa-
tients with a single C. difficile episode (Drudy et al. 2004),
suggesting that the ability to mount an anti-SLP antibody
response may significantly determine a patient’s disease state.
Collectively, these studies support the hypothesis of an impor-
tant role for SLPs in innate and adaptive immunity.
A limited number of examples suggest targeting SLPs could
be a potential therapeutic approach to combat CDAD. O’Brien
et al. (2005) demonstrated that prophylactic administration of
SLP anti-sera significantly prolonged survival of hamsters that
were lethally challenged. Subsequent studies of active immu-
nization of mice using crude cell wall extracts showed a sig-
nificant reduction in C. difficile colonization of the immunized
group compared to controls (Péchiné et al. 2007). Currently,
C. difficile infections are treated with a course of antibiotics,
which can alter the composition of the gut microbiome and
increase the selection pressure on the organism, which can in
turn lead to antibiotic resistance. Targeting essential bacterial
virulence factors, such as SLPs, is an alternative therapeutic
strategy to conventional antibiotic use, which can address the
risk of rising antibiotic resistance (Cegelski et al. 2008;
Clatworthy et al. 2007; Lynch and Wiener-Kronish 2008).
Single-domain antibodies isolated from the variable do-
mains of Camelidae species heavy-chain IgGs (referred to as
VHHs or BNanobodies^) are attractive candidates to explore
for oral therapy because these domains retain the affinity and
specificity of conventional monoclonal antibodies (mAbs),
but possess added biophysical advantages such as resistance
to extreme pH and proteases (Harmsen and De Haard 2007;
Holliger and Hudson 2005; Holt et al. 2003). Single-domain
antibodies have been isolated to many targets in the context of
infection and immunity (Hussack and Tanha 2010;
Wesolowski et al. 2009), and their potential as oral therapeu-
tics has been well documented (Harmsen et al. 2007; van der
Vaart et al. 2006; Virdi et al. 2013).
The use of antibodies as neutralizing agents, in addition to
studies implicating C. difficile SLPs as mediators for cell-host
interactions (Calabi et al. 2002; Drudy et al. 2001), has in-
spired the current study. Here, VHHs to SLPs from
C. difficile strain QCD-32g58 were selected from an immune
llama VHH phage display library. The antibodies were then
functionally and biochemically characterized with respect to
structure, affinity, specificity, aggregation state, thermostabil-
ity, resistance to pepsin digestion, and the ability to bind and
inhibit the motility of C. difficile cells.
Materials and methods
Isolation of SLPs from C. difficile strains 630
and QCD-32g58
C. difficile SLPs were isolated using low-pH glycine extrac-
tion as described previously (Dubreuil et al. 1988) with the
following modifications. Briefly, cells from strains QCD-
32g58 (GenBank accession no. AAML00000000; Janvilisri
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et al. 2009; Forgetta et al. 2011) and 630 (GenBank accession
no. AM180355.1; Janvilisri et al. 2009; Monot et al. 2011;
Sebaihia et al. 2006) were cultured overnight on a BHI-agar
plate, scraped, resuspended in 500 μl of 0.2 M glycine, pH
2.2, and incubated for 10 min at room temperature. Bacterial
cells were removed by centrifugation at 13,000 rpm in a
benchtop centrifuge and the SLP-containing supernatant
transferred to a 4-ml Amicon filter device with a 5000 Da
MWCO (EMD Millipore, Toronto, ON, Canada) for buffer
exchange. The SLPs were washed twice with 4 ml of sterile
H2O and collected in 1 ml sterile H2O. A 10-μl aliquot was
mixed with SDS-PAGE loading buffer containing β-
mercaptoethanol and analyzed on a 12.5 % SDS-PAGE gel.
Size-exclusion chromatography (SEC) was used to further
purify the isolated SLP proteins after extraction. To this end,
a Superdex™ 200 10/30 GL column (GE Healthcare, Baie-
d’Urfé, QC, Canada) was equilibrated with running buffer
(10 mM HEPES buffer, pH 7.5, 150 mM NaCl), and 500 μl
of SLP extracts were loaded and eluted over one column vol-
ume as previously described (Fagan et al. 2009). Eluted frac-
tions were analyzed on a 12.5 % SDS-PAGE for content. All
fractions were stored at 4 °C for later use.
Llama immunization, VHH phage display library
construction, and panning
Llama immunization, library construction, and panning were
carried out as described previously (Hussack et al. 2012).
Briefly, for llama immunization, one adult male llama (Lama
glama) was immunized subcutaneously four times at its lower
back with a mixture of QCD-32g58 and 630 SLP antigens at
the Cedarlane animal facility (Burlington, ON, Canada) and
according to the company’s animal safety protocol. On the
first day, a pre-immune bleed was conducted and a mixture
of two antigens (100 μg of each antigen diluted in PBS in total
volume of 1.25 ml) and Freund’s complete adjuvant (1.25 ml;
Sigma, Oakville, ON, Canada) was injected into the llama.
The llama received three additional boosts with 100 μg of
the same antigen mixture with Freund’s incomplete adjuvant
(Sigma) on days 28, 47, and 66. Blood (10–15 ml) was col-
lected on days 59 and 72. Total (un-fractionated) serum was
analyzed for a specific response to QCD-32g58 and 630 SLPs
by enzyme-linked immunosorbent assay (ELISA). Llama se-
rum from day 72 was fractionated into conventional (IgG1)
and heavy-chain antibody (IgG2 and IgG3) components and
analyzed for specific binding to QCD-32g58 and 630 SLPs by
ELISA (Hussack et al. 2012). Lymphocytes were isolated at
Cedarlane. A VHH phage display library was constructed
using approximately 2×107 lymphocytes (as the source of
VHH repertoire genes) collected from the day 72 blood. The
size of the library was estimated to be 2.7×108 transformants.
The VHH DNA fragments from 92 colonies were PCR-
amplified and sequenced to assess library diversity. Library
phage was prepared and 1012 colony-forming units (CFU) of
library phage was used as input for the first round of panning
against 10 μg of SEC-purified QCD-32g58 SLPs coated onto
NuncMaxisorp™ wells (Thermo Fisher, Ottawa, ON, Canada).
For the following three rounds of panning, 1011 CFU phage was
used as the input. Phage ELISAwas performed to identify indi-
vidual phage displaying VHHs specific to QCD-32g58 and 630.
VHH subcloning, soluble expression, purification,
and SEC
Positive VHH binders identified by phage ELISA were
subcloned, expressed in 1-l cultures and purified by
immobilized metal-ion affinity chromatography as described
(Hussack et al. 2012). Purified proteins were assessed for pu-
rity and integrity by SDS-PAGE. The aggregation status and
elution volumes of VHHs were determined by SEC using a
Superdex™ 75 10/300 GL column (GE Healthcare) as de-
scribed (Hussack et al. 2012; Kim et al. 2012a). Elution vol-
umes were used to determine apparent molecular masses
(Mapps) of VHHs from a set of protein standards (Hussack
et al. 2011b). SEC chromatograms were normalized as de-
scribed (Kim et al. 2012b).
SPR analysis
The binding of all VHHs to immobilized QCD-32g58 SLP,
630 SLP, and QCD-32g58 SLP LMWsubunit was determined
by surface plasmon resonance (SPR) using a Biacore 3000
(GE Healthcare). The SLPs were SEC-purified as described
above prior to immobilization at concentrations of 50μg/ml in
10 mM acetate buffer on a CM5 sensor chip using the amine
coupling kit supplied by the manufacturer (GE Healthcare). In
all instances, analyses were carried out at 25 °C in 10 mM
HEPES running buffer, pH 7.4, containing 150 mM NaCl,
3 mM EDTA, and 0.005 % surfactant P20 at a flow rate of
20 μl/min. For regeneration, the surfaces were washed thor-
oughly with either running buffer (SLP_VHH2, SLP_VHH26,
SLP_VHH49, and SLP_VHH50), 10 mM glycine-HCl, pH
3.0, for 3 s (SLP_VHH22), 10 mM glycine-HCl, pH 2.5, for
3 s (SLP_VHH5 and SLP_VHH46), or 50 mM NaOH for 3 s
(SLP_VHH12 and SLP_VHH23). Due to the loss of surface
activity after 50 mM NaOH surface regeneration, a fresh sur-
face was made and used to study the binding activity of
SLP_VHH12 and SLP_VHH23. Data were analyzed with
BIAevaluation 4.1 software.
Tm measurements by circular dichroism spectroscopy
The thermal unfolding profile of each antibody was obtained
using circular dichroism (CD) according to a previously de-
scribed method (Hussack et al. 2011b) with minor modifica-
tions. Briefly, after dialysis into 10 mM sodium phosphate
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buffer, pH 7.0, a 1-mm cuvette containing 200 μl of a VHH at
50 μg/ml was used to obtain CD spectra from 180–260 nm
using a J-810 spectropolarimeter (Jasco Inc., Easton, MD,
USA). The temperature was increased from 30 to 96 °C at a
temperature ramp rate of 1 °C/min, and data were collected
every 2 °C at a spectral scan rate of 50 nm/min and 1-mm
bandwidth.
Disulfide bond mapping by MS
Disulfide bond mapping of SLP_VHH22 and SLP_VHH50,
each with four Cys residues, was performed essentially as
described (Kim et al. 2012b; Hussack et al. 2011b). Briefly,
tryptic fragments for subsequent mass spectrometry (MS)
analysis were prepared as described (Kim et al. 2012a).
Aliquots of VHH proteolytic digests were resuspended in
0.1 % (v/v) formic acid (aq) and analyzed by nanoflow
reversed-phase HPLC MS (nanoRPLC-ESI-MS) with data-
dependent analysis (DDA) using collision-induced dissocia-
tion (CID) on a nanoAcquity UPLC system coupled to a Q-
TOF Ultima™ hybrid quadrupole/TOF mass spectrometer
(Waters, Milford, MA, USA). The peptides were first loaded
onto a 300 μm I.D. × 5 mm C18 PepMap100 μ-precolumn
(Thermo Fisher) and then eluted into a 100 μm I.D. × 10 cm
1.7-μm BEH130C18 column (Waters) using a linear gradient
from 0 to 36 % solvent B (acetonitrile+0.1 % formic acid)
over 36 min followed by 36–90 % solvent B for 2 min.
Solvent A was 0.1 % formic acid in water. The peptide MS2
spectra were compared with VHH protein sequences using the
Mascot™ database searching algorithm (Matrix Science,
London, UK). The MS2 spectra of the disulfide-linked pep-
tides were de-convoluted using the MaxEnt 3 program
(Waters) for de novo sequencing to confirm and/or determine
the exact disulfide linkage positions.
Pepsin digestion assay
To assess the degree of resistance of each antibody to pepsin (a
common protease in the digestive tract), SLP-specific VHHs
were subjected to pepsin digestion as previously described
(Hussack et al. 2011b) at enzyme concentrations ranging from
1.25 to 100 μg/ml. Triplicate independent experiments were
conducted, and densitometry analysis values were averaged to
determine percent pepsin resistance.
Epitope characterization by Western blot analysis
To determine subunit specificity of the VHHs and the nature of
their epitope (conformational or linear), denaturing Western
blots of strain QCD-32g58 SLPs were probed with anti-SLP
VHHs. SLPs (5 μg/lane) were separated on 12.5 % SDS-
PAGE gels and transferred to PVDF membranes at 100 V
for 1 h. Membranes were blocked for 2 h with 2 % (w/v) milk
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in PBS and probed with various VHHs (50 μg/5 ml PBS-T
[PBS/0.05 % (v/v) Tween 20]) for 1 h. Membranes were
washed three times in PBS-T followed by addition of
mouse anti-His IgG-alkaline phosphatase (AP) conjugate
(Abcam, Cambridge, MA, USA), diluted 1:5000 in blocking
buffer, for 1 h. Membranes were washed as before and
subjected to AP substrate (Bio-Rad, Mississauga, ON,
Canada) for 10 min, washed in distilled H2O and air dried.
A corresponding stained SDS-PAGE gel of the SLPs was
used as reference.
Whole cell ELISA
C. difficile strains were grown on BHI supplemented agar
under anaerobic conditions at 37 °C overnight. Cells were
resuspended in PBS containing 3 % (v/v) formalin and left
for 24 h at 4 °C. Cells were washed two times with PBS and
resuspended to OD600 0.08. NuncMaxiSorp® Flat-Bottom
plates were coated with 100 μl of formalin-fixed cells over-
night at 37 °C. Plates were blocked with 2 % (w/v) milk in
PBS. His6-tagged VHHs specific for SLP were then added
(10 μg/ml in PBS-T) and plates incubated at 37 °C for 1 h in
a shaker incubator. Plates were washed three times with PBS-T
and then incubated with rabbit anti-His6 antibody-horse radish
peroxidase conjugate (1:5,000 in PBS-T, of a 1 mg/ml stock;
Cedarlane) for 1 h at 37 °C. Following washing as above, the
antibody was detected with TMB substrate for 10 min and the
reaction stopped with 1 M H3PO4. Samples were analyzed in
triplicate, and the absorbance was measured at 450 nm.
Motility assay
An in vitro motility assay was used to determine if the isolated
VHHs were capable of binding whole C. difficile cells and
preventing motility. Sterile culture tubes containing 5 ml
0.175 % agar-BHI media supplemented with 0.5 % (w/v)
Bacto-yeast extract, 0.12 % (w/v) NaCl, and 25 or 50 μg/ml
VHH, were stabbed with a fresh culture of strain QCD-32g58
as previously described (Twine et al. 2009) and incubated in
anaerobic conditions at 37 °C for 23 h. Photographs were
taken at 23 h postinoculation to monitor the effects of each
antibody on motility of the strain relative to a control which
did not receive antibody.
Results
Purification of SLPs from 630 and QCD-32g58 C. difficile
strains
SLPs from C. difficile strains 630 and QCD-32g58 (Figs. 1a
and S1) were first purified by low pH glycine extraction.
When analyzed by reducing SDS-PAGE, the HMW and
LMW SLPs migrated to ~45 and ~33 kDa (630) and ~45 and
~34 kDa (QCD-32g58) (Fig. 1b), which is close to the pre-
dictedMs of 39.5/34.2 kDa and 44.2/33.9 kDa (HMW/LMW
SLPs, from 630 and QCD-32g58 strains, respectively) and
consistent with others who ran SLPs under reducing SDS-
PAGE conditions (Calabi et al. 2001; Mauri et al. 1999). To
increase SLP purity, low pH extracted-SLP preparations were
injected over a Superdex™ 200 SEC column (Fig. 1c, left
panel). Fractions from the two major peaks and one minor
peak were analyzed by 12.5 % SDS-PAGE (Fig. 1c, right
panel). The first peak (with an elution volume of 10.8 ml),
when analyzed by SDS-PAGE, confirmed the presence of
both HMW and LMW subunits of SLPs. The second
mino r peak e l u t i ng a t app rox ima t e l y 15 ml
corresponded to the LMW subunit. The LMW subunit
could only be isolated from QCD-32g58. The last major
SEC peak was not detectable on SDS-PAGE despite the
strong A280nm signal, which could represent breakdown
products of the HMW subunit, as it is unstable once
separated from the LMW subunit (Fagan et al. 2009),
and since the HMW subunit was not isolated in free-
form from any of the fractions collected. The SEC-
purified QCD-32g58 SLP and LMW SLP were used in
library panning and SPR experiments.
Fig. 1 Isolation of SLP-specific VHHs. a Schematic diagram of
C. difficile S-layer proteins. Top, SLP low-molecular-weight (LMW)
and high-molecular-weight (HMW) subunits are expressed as a single
polypeptide chain before cleavage with Cwp84 cysteine protease. The
cleavage site of the signal sequence (SS) is also shown. Bottom, after
Cwp84-mediated cleavage, the LMW and HMW subunits associate in
the orientation relative to the bacterial cell wall shown. b SDS-PAGE,
run under reducing (R) conditions, of SLPs purified from 630 and QCD-
32g58 (QCD) strains using low pH extraction. c Left, SEC Superdex™
200 profile of SLPs and, right, reducing SDS-PAGE gel of the
corresponding fractions. Only LMW subunit from QCD-32g58 could
be purified (shown with an asterisk). The HMW subunit could not be
purified from either strain. d Work flow overview and llama
immunization schedule for the isolation of SLP-specific VHHs. FCA
Freund’s complete adjuvant, FIA Freund’s incomplete adjuvant, Ag
QCD-32g58 SLP. e Phage ELISA demonstrating the binding of phage-
displayed VHHs to immobilized SLPs. f Amino acid sequence alignment
of VHHs isolated from panning that were expressed and characterized in
this study. Positions 42, 49, 50, 52, and 55 are numbered. Numbering and
CDR designations are according to IMGT (http://imgt.cines.fr/). g
Unusual disulfide bonds (DSB) identified in SLP_VHH22 and SLP_
VHH50 by mass spectrometry fingerprinting analysis
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Llama immunization, library construction, and panning
for SLP-binding VHHs
VHHs isolated from naive libraries tend to have low target
antigen affinities (KDs in the μM range; Tanha et al. 2002;
Yau et al. 2005); therefore, an immune llama library was con-
structed to isolate high affinity binders to SLPs, using a mix-
ture of 630 and QCD-32g58 SLPs as immunogens. A male
llamawas immunized using an equal mixture of both antigens,
according to the schedule in Fig. 1d. Llama sera and blood
were processed and a heavy-chain IgG response to QCD-
32g58 SLP was determined by ELISA (data not shown). An
immune phage display library was constructed and was sub-
jected to four rounds of panning against SLPs from QCD-
32g58 (Fig. 1d). To identify QCD-32g58-specific binders af-
ter three rounds of panning, a total of 50 TG1 E. coli colonies
containing the phagemid vector were picked at random for
monoclonal phage ELISA to identify binders to QCD-32g58
SLP (data not shown). Nine unique VHHs were identified, and
the phage ELISA is shown for those clones (Fig. 1e). The
amino acid sequence composition of the nine unique antibod-
ies (Fig. 1f) confirmed their identity as VHHs (not VHs), ac-
cording to characteristic camelid VHH residues at positions
42, 49, 50, and 52 (Harmsen et al. 2000). The VHHs were
deno ted SLP_VHH2, SLP_VHH5, SLP_VHH12,
SLP_VHH22, SLP_VHH23, SLP_VHH26, SLP_VHH46,
SLP_VHH49, and SLP_VHH50 (Fig. 1f). Based on the phage
ELISA (Fig. 1e), all nine clones showed specific binding to
SLP from QCD-32g58 while only SLP_VHH2, and less
strongly SLP_VHH26, cross-reacted to SLP from strain 630.
This is not surprising as the VHH library was panned against
QCD-32g58. The CDR3 length distribution among the nine
antibodies isolated varied. SLP_VHH2, SLP_VHH5, and
SLP_VHH26 have the shortest CDR3 with 16 residues.
SLP_VHH12, SLP_VHH22, and SLP_VHH23 all have a sig-
nificantly long CDR3, with lengths of 28, 25, and 28 residues,
respectively. Many of the clones shared high sequence homol-
ogy, while SLP_VHH22 and SLP_VHH50 contained an addi-
tional cysteine residues at position 55 and in complementarity-
determining region 3 (CDR3). The presence of a cysteine at
residue 55 is characteristic of VHH subfamilies 3 and 4
(Harmsen et al. 2000). These two VHHs were the only binders
to belong to the VHH subfamily 3 while the other VHHs were
subfamily 1. Cys55 and CDR3 Cys have the potential to form
an interloop disulfide bond to restrict the fold of the relatively
long CDR3 and enhance the stability of the antibodies
(Govaert et al. 2012; Kim et al. 2014). This indeed was shown
to be the case for both SLP_VHH22 and SLP_VHH50 byMS-
based disulfide bond mapping experiments (Fig. 1g;
Table S1). However, and unexpectedly, disulfide bond map-
ping also revealed that these noncanonical Cys residues were
also involved in forming other, unusual disulfide linkages. In
SLP_VHH22, Cys55 and CDR3 Cys form disulfide linkages
with Cys23, which typically forms a highly conserved disul-
fide linkage with Cys104 in VHHs, and similarly in
SLP_VHH50, Cys55 forms a disulfide linkage with Cys104.
Expression and biophysical characterization
of SLP-binding VHHs
The nine SLP-binding VHHs isolated from panning were
subcloned, expressed, and purified. We observed high and
variable expression yields of the clones (15–75 mg/l of bacte-
rial culture). Purified VHHs were subjected to SEC analysis,
and all were nonaggregating monomers as expected, with a
mean±SD Mapp of 15.9±2.4, similar to the mean±SD theo-
retical mass of 16.3±0.6 expected for monomeric VHHs
(Fig. S2a; Table 1). We further characterized the panel of
VHHs by determining midpoint unfolding temperatures
(Tms) by CD spectroscopy and VHH sensitivities to the major
gastrointestinal enzyme pepsin by proteolytic digestion as-
says. Both techniques provide valuable information on VHH
stability and aid in the selection of lead candidates. From the
heat-induced unfolding curves, the VHH Tms ranged from
62.3 to 75.4 °C (Fig. S2b; Table 1) with all VHHs folded at
physiological temperatures. Antibody unfolding followed a
single phase transition as expected. Next, all VHHs were sub-
jected to a pepsin digestion assay at pH 2.0, beginning with a
biologically relevant concentration of pepsin at 100 μg/ml
(Fig. S3). Under digestion conditions, the VHHs exhibited a
loss of the C-terminal tag, consistent with our previous find-
ings (Hussack et al. 2011b; To et al. 2005), and therefore lower
bands corresponding to a M that is ~2 kDa less than the band
corresponding to the full-length VHH are considered as resis-
tant to enzymatic digestion. As expected, resistance to pepsin
decreased as a function of enzyme concentration (Table 1;
Fig. S3). High pepsin resistance was observed at lower pepsin
concentrations and the majority of VHHs (five out of nine)
showed moderate to high resistance at 25 μg/ml pepsin con-
centration. SLP_VHH2 and SLP_VHH22 showed the greatest
pepsin resistance with an average of 12±3.1 % and 19.6±
0.8 % VHH remaining after digestion for 1 h with 100 μg/ml
of enzyme, respectively (Table 1). At lower pepsin concentra-
tions (50 μg/ml), 15.3±5.0 % of SLP_VHH2, 46.5±10.0 % of
SLP_VHH22, 21.9±9.8 % of SLP_VHH23 and 2.8±2.0 % of
SLP_VHH12 remained undigested after 1 h.
Binding analysis of VHHs to SLPs
For affinity determination, monomeric fractions of VHHs col-
lected from the SEC column were analyzed by SPR. VHHs
were injected over CM5-immobilized and SEC-purified
QCD-32g58 SLP, 630 SLP, and the QCD-32g58 LMW sub-
unit, at various concentrations to characterize the binding
specificity and affinity (Fig. 2a, b). In the first experiment,
all nine VHHs were shown to bind QCD-32g58 SLP
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(Fig. 2a; Table 2). None of the VHHs bound to the reference
surface on which a similar amount of a control protein was
immobilized (data not shown). KDs were determined from
kinetic rate constants (SLP_VHH5, SLP_VHH12,
SLP_VHH23, and SLP_VHH46) or by steady-state analysis
(SLP_VHH2, SLP_VHH22, SLP_VHH26, SLP_VHH49, and
SLP_VHH50). The VHHs SLP_VHH5, SLP_VHH12,
SLP_VHH23, and SLP_VHH46 had the highest affinities to
QCD-32g58 SLP (KDs of 3–6 nM). SLP_VHH12 and
SLP_VHH23 required the use of 50 mM NaOH for their
complete dissociation from the QCD-32g58 SLP sur-
face, which resulted in loss of surface activity; there-
fore, a fresh surface was made, and only a single
injection of each was used to analyze the binding activ-
ity of these two VHHs. SLP_VHH49 and SLP_VHH50
had aff ini t ies of 48 and 75 nM, respect ively.
SLP_VHH2, SLP_VHH22, and SLP_VHH26 had the
weakest affinities to QCD-32g58 SLP with KDs of
230, 180, and 580 nM, respectively. These three
VHHs, as well as SLP_VHH49, showed a complex bind-
ing pattern to QCD-32g58 SLP in that at low antibody
concentrations, high-affinity binding was observed,
while at high antibody concentrations lower affinity
binding was observed, which maybe an indicator of an-
tigen heterogeneity. Collectively, the SPR data con-
firmed the ability of the VHHs to bind QCD-32g58 SLP.
Table 1 Summary of VHH molecular mass, thermal stability, and pepsin resistance data
VHH M (kDa) Mapp (kDa) Tm (°C) Pepsin resistance (%)
a
100 μg/ml 10 μg/ml 1.25 μg/ml
SLP_VHH2 15.71 14.5 62.3 12.0±3.1 55.3±13.1 99.0±1.3
SLP_VHH5 15.61 14.2 70.3 0 10.3±1.5 76.1±15
SLP_VHH12 17.00 16.6 73.7 0 77.8±3.9 99.4±1.9
SLP_VHH22 16.38 17.3 74.6 19.6±0.8 83.1±3.3 99.0±1.5
SLP_VHH23 17.02 19.1 75.4 0 93.4±5.9 97.2±1.7
SLP_VHH26 15.72 14.2 71.9 0 50.8±2.5 96.6±0.1
SLP_VHH46 15.83 16.6 66.3 0 55.6±4.5 96.6±1.6
SLP_VHH49 16.71 11.9 64.8 0 0 59.7±14.2
SLP-VHH50 16.25 18.7 70.3 0 15.9±7.9 89.9±3.1
M theoretical (formula) molecular mass, Mapp apparent molecular mass determined by SEC, Tm melting temperature
a Percent VHH (mean±SE) remaining after digestion for 1 h at 37 °C and pH 2.0 with 100, 10, or 1.25 μg/ml of pepsin (n=3)
Fig. 2 Characterization of VHH binding to SLPs. a, b SPR sensorgrams
illustrating the binding of VHHs to immobilized QCD-32g58 SLP (a) and
QCD-32g58 LMW SLP (b). cWestern blots demonstrating that a subset
of VHHs recognizes a liner epitope on the LMW subunit of QCD-32g58
SLP. QCD QCD-32g58
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Next, we expanded our SPR analyses to determine if the
VHHs cross-reacted to 630 SLP. In a similar approach to the
QCD-32g58 SLP, 630 SLP were immobilized on a CM5 sen-
sor chip and VHHs injected at various concentrations.
Consistent with our earlier phage ELISA results (Fig. 1e),
only SLP_VHH2 and SLP_VHH26 bound 630 SLP (data not
shown). The affinities of SLP_VHH2 and SLP_VHH26 to 630
SLP were 1 and 2 μM, respectively, indicating a ~5-fold
weaker binding affinity to 630 SLP than QCD-32g58 SLP.
Finally, we set out to explore the nature of the QCD-32g58
SLP epitope recognized by the VHHs, specifically if they
bound the HMWor LMW SLP subunit. As previously shown
(Fig. 1c), we were unable to purify the HMWSLP subunit and
purified only a small amount of the QCD-32g58 LMW SLP
subunit which limited our SPR analysis against the LMWSLP
to a single concentration screen. At 200 nM VHH concentra-
tions, all of our VHHs bound the QCD-32g58 LMW subunit
(Fig. 2b; Table 2). A similar affinity rank pattern to the full
SLP was observed: SLP_VHH5, SLP_VHH12, SLP_VHH23,
and SLP_VHH46 had the lowest KDs of all VHHs tested,
SLP_VHH2 and SLP_VHH26 had the highest KDs, and the
remaining VHHs had intermediate KDs. Interestingly, the
VHHs bound with higher affinities to the LMW SLP than
the full SLP, suggesting a more optimal epitope presentation
on the SPR chip for the LMW SLP. Collectively, the SPR
binding data indicated the epitopes recognized by anti-SLP
VHHs reside entirely in the LMW subunit of QCD-32g58
SLP, and that some level of cross-reactivity to 630 SLP, pre-
sumably with the LMW subunit, was evident for a subset of
the VHHs. These findings are consistent with earlier reports
that showed the LMW SLP subunit is immunodominant
(Spigaglia et al. 2011) and that cross-reactive antibodies to
the LMW SLP subunit from different C. difficile ribotypes
are rare due to the low amino acid sequence homology
(Calabi et al. 2001). To determine if the QCD-32g58 SLP
epitope recognized by the VHHs was linear or conformational,
a denaturing SDS-PAGE-Western blot was performed. QCD-
32g58 SLPs were separated in an SDS-PAGE gel under re-
ducing conditions, transferred to a PVDF membrane, and
probed with individual VHHs followed by detection with an
anti-His6 IgG conjugated to alkaline phosphatase (Fig. 2c). A
nontransferred SDS-PAGE was run to demonstrate the pres-
ence of both HMW and LMW QCD-32g58 SLP subunits in
the samples (Fig. 2c, left panel). Moreover, a Western blot
performed against transferred VHHs confirmed all VHHs had
their His6 tag. The VHHs SLP_VHH5, SLP_VHH12,
SLP_VHH23, SLP_VHH46, and SLP_VHH49 bound the
LMW subunit of QCD-32g58 SLP, consistent with our SPR
results (Fig. 2b), and indicating that these VHHs recognized a
linear epitope. The remaining VHHs were weakly positive, or
negative altogether, by Western blot for binding to the LMW
subunit of QCD-32g58 SLP, indicating that they may recog-
nize conformational epitopes, or have too low of an affinity
and/or koffs too rapid to produce a detectible signal.
Binding of VHHs to C. difficile cells
ELISAwas used to determine the ability of each VHH to bind
to a number of C. difficile clinical isolates. All SLP-specific
VHHs in this study bound bacterial cells of strain QCD-32g58
(Fig. 3a). In addition, strong reactivity of each VHH to the
bacterial cell surface of a number of other C. difficile isolates
which belong to the same 027 hypervirulent ribotype (BI-1,
BI-7, 196, R20291) as well as ribotype 001 (strain 001_01)
was observed. In contrast, VHH reactivity to the cell surface of
representative strains from other ribotypes (012, 017, 023, and
Table 2 SLP-specific VHH binding data
VHH QCD-32g58 SLP QCD-32g58 LMW SLP
a
kon (/M/s) koff (/s) KD (nM) Rmax (RU) kon (/M/s) koff (/s) KD (nM) Rmax (RU)
SLP_VHH2 n.d.
b n.d.b 230 277 1.5×105 1.3×10−2 90 26
SLP_VHH5 8.2×10
4 4.6×10−4 6 100 1.4×105 4.1×10−4 3 151
SLP_VHH12 1.2×10
5 3.4×10−4 3 142 1.4×105 1.2×10−4 1 131
SLP_VHH22 n.d.
b n.d.b 180 100 1.3×105 1.1×10−3 8 114
SLP_VHH23 9.4×10
4 3.7×10−4 4 98 1.1×105 3.2×10−4 3 72
SLP_VHH26 n.d.
b n.d.b 580 288 2.1×105c 9.7×10−2c 460c 5c
SLP_VHH46 1.1×10
5 3.4×10−4 3 83 1.5×105 3.2×10−4 2 181
SLP_VHH49 n.d.
b n.d.b 48 197 5.9×105 1.2×10−2 20 231
SLP-VHH50 n.d.
b n.d.b 75 175 1.9×105 2.7×10−3 14 154
a Binding kinetics were determined from 200 nM VHH injections as a binding screen
bA steady-state model was used to obtain the KD. Therefore, rate constants are not determined (n.d.)
c The affinity and rate constants should be interpretedwith caution as the experimental Rmax is very low, andmultiple injection are required to confirm the
values
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078) was far more restricted, suggesting considerable diversi-
ty in the LMW SLP epitopes displayed among distinct line-
ages of C. difficile. Interestingly, SLP_VHH5 was able to rec-
ognize all C. difficile isolates tested, representing a number of
distinct ribotypes. While both SLP_VHH2 and SLP_VHH26
were shown to cross-react to 630 SLP in phage ELISA and
SPR assays, it was only SLP_VHH2 that cross-reacted to 630
SLP in cell binding assays.
C. difficile motility assays
Despite a lack of evidence in the literature relating SLP func-
tion to bacterial motility, we nonetheless sought to test the
ability of SLP-specific VHHs to inhibit C. difficile (QCD-
32g58 strain) motility. Culture tubes containing BHI-agar sup-
plemented with VHHs at either 25 μg/ml (~1.5 μM) or
50 μg/ml (~3 μM) were inoculated with stabs of C. difficile
and cultured for 23 h. Growth was monitored and
photographed 23 h postinoculation (Fig. 3b). Motile cells
displayed a diffuse spreading flare of growth at the bottom
of the inoculating stab. The results demonstrated that at 23 h
postinoculation using 25-μg/ml antibody concentrations,
SLP_VHH5 and SLP_VHH46 completely inhibited
C. difficile motility. SLP_VHH50 showed slight inhibition of
motility at 25 μg/ml. The remaining VHHs did not inhibit
motility at concentrations of 25 μg/ml. To test whether motil-
ity inhibition was concentration dependent, we doubled the
antibody concentration to 50 μg/ml (Fig. 3b). Similar to the
lower concentration, SLP_VHH5 and SLP_VHH46 clearly
inhibited C. difficile motility. Increasing the concentration of
SLP_VHH50 to 50 μg/ml resulted in complete inhibition of
C. difficile motility.
Discussion
The outer surface of many bacteria is covered in a proteina-
ceous coat called the S-layer (surface layer) that is involved in
growth, function, and interaction with the host (Fagan and
Fairweather 2014). In Gram-positive species, such as
C. difficile, SLPs have been shown to play a role in adherence
to gastrointestinal tract cells and extracellular matrix compo-
nents (Calabi et al. 2002; Takumi et al. 1991), and recently,
SLPs were shown to have a role in activating innate and adap-
tive immunity through TLR4 (Ryan et al. 2011) and induce
pro-inflammatory cytokines (Bianco et al. 2011; Collins et al.
2014). It has been known for several years that patients with
recurrent episodes of C. difficile have significantly lower anti-
Fig. 3 SLP-specific VHHs bind C. difficile cells and inhibit motility. a
Whole cell ELISA demonstrating the binding of VHHs to various
C. difficile strains. b C. difficile (QCD-32g58) stabs after 23 h
comparing the effects of 25 and 50 μg/ml VHH concentrations on
bacterial motility. SLP_VHH5, SLP_VHH46, and SLP_VHH50 showed
inhibition of C. difficile motility, denoted with arrows at the tip of the
stabs
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SLP IgM titers than patients experiencing a single episode of
C. difficile infection (Drudy et al. 2004). In addition, active
immunization of hamsters with SLPs elucidated partial pro-
tection when challenged with C. difficile (Ni Eidhin et al.
2008). Collectively, this suggests that SLPs may have a criti-
cal role in C. difficile pathogenesis and virulence in humans,
making them targets for diagnostic probes, vaccine de-
velopment and novel therapeutic agents. In C. difficile,
mature SLPs consist of HMW and LMW subunits which
are produced by proteolytic cleavage of a single poly-
peptide chain (SlpA). In a mature SLP, the LMW sub-
unit is displayed toward the environment and shows
higher sequence variability than the HMW subunit
(Calabi and Fairweather 2002; Merrigan et al. 2013).
To explore the use of antibodies targeting novel C. difficile
virulence factors, we produced high-affinity llama VHHs to
C. difficile SLPs. We isolated SLPs from the hypervirulent
QCD-32g58 strain (027 ribotype) and the 630 reference strain
(012 ribotype), immunized a llama with both simultaneously,
isolated several VHHs, and characterized these antibodies.
Immunization with SLPs generated a strong heavy-chain an-
tibody immune response in the llama, indicating the SLPs
were very immunogenic. From a phage display library panned
with SLPs from QCD-32g58, nine unique VHHs were isolat-
ed. By phage ELISA and SPR, all recognized QCD-32g58
SLP, while two (SLP_VHH2 and SLP_VHH26) cross-reacted
to 630 SLP, with at least more than half of the VHHs recog-
nizing linear epitopes. SPR binding of VHHs revealed high-
affinity binding to QCD-32g58 SLP with KDs as low as 3–
6 nM, but nonetheless, several VHHs also had significantly
higher KDs, as high as 580 nM, a KD range pattern frequently
seen with VHHs obtained from immune VHH phage display
libraries. Interestingly, the four VHHs with the highest affini-
ties (3–6 nM) all recognize linear epitopes. Despite immuniz-
ing and panning with the QCD-32g58 whole SLP, all of the
VHHs targeted the highly variable LMW subunit. The HMW
subunit is conserved across C. difficile isolates and the LMW
subunit is considerably more variable (Calabi and Fairweather
2002; Merrigan et al. 2013). In agreement with our findings,
between the LMW and HMW subunits, the LMW one has
been shown to be the immunodominant antigen elsewhere
(Ausiello et al. 2006; Péchiné et al. 2007).
With respect to thermostability, VHHs showed Tms as high
as 75 °C, although engineered VHHs with higher Tms have
been previously reported, in the range of 79–94 °C (Hussack
et al. 2011b; Zabetakis et al. 2014). VHHs also showed signif-
icant resistance to the GI enzyme pepsin with two VHHs hav-
ing pepsin resistance as high as 20 % at a physiologically
relevant pepsin concentration (100 μg/ml). Noticeably, three
out of the four VHHs that showed pepsin resistance at a rela-
tively high enzyme concentration (50 μg/ml) have the highest
Tms (73.7–75.4 °C), and SLP_VHH22, which was the most
resistant VHH, had a pair of Cys at positions 55 and in CDR3
that formed an extra disulfide linkage. Previously, a positive
correlation was found between pepsin resistance and Tm, and
mutations that increased Tm also increased pepsin resistance
(Hussack et al. 2011b). The extra noncanonical disulfide link-
age in SLP_VHH22 may be a contributor to its high Tm and/or
pepsin resistance. Previously, similar noncanonical (inter-
CDR1-CDR3; inter-CDR2-CDR3) disulfide linkages were
shown to increase the stability of VHHs (Govaert et al. 2012;
Zabetakis et al. 2014). In particular, a disulfide linkage formed
between a pair of Cys residues at positions 55 and in CDR3
improved the Tm of a VHH by several degrees (Zabetakis et al.
2014). However, we find that in addition to forming the ex-
pected noncanonical disulfide linkage between them, Cys55
and CDR3 Cys also pair up with Cys23 or Cys104—which
are involved in a highly conserved canonical disulfide linkage
in VHHs—to form unusual disulfide linkages not reported
previously. Whether these unusual disulfide linkages are the
result of heterologous expression in E. coli is not clear to us. It
is also unclear if they are present in significant proportions of
the VHH population.
We tested the ability of VHHs to bind C. difficile whole
cells in ELISA, which presents the SLP protein in a more
natural context for antibody binding. All nine VHHs bound
QCD-32g58 cells and, not surprisingly, all other 027 ribotype
strains tested, including BI-1, BI-7, 196, and R20291, which
have identical LMW subunit SLP sequences to QCD-32g58.
These results confirm the feasibility of using purified, out-of-
natural-context SLP as an immunogen and target antigen for
panning experiments for obtaining anti-SLP antibodies that
recognize parent cells equally well. As well, the panel of
VHHs all bound to a 001 ribotype strain, indicating that at
least the LMW subunit of 001 ribotype strain should have
high sequence identity to the SLP LMW subunits from the
aforementioned 027 ribotypes. SLP_VHH2 showed binding
to 630, which was expected given the evidence of cross-
reactivity in ELISA and SPR. SLP_VHH26 did not show
binding to 630 cells, despite earlier ELISA and SPR evidence
showing binding to 630 SLPs. Interestingly, SLP_VHH5
bound all ribotypes tested in the cell ELISA format, indicating
the antibody is broadly cross-reactive. Why SLP_VHH5 failed
to recognize 630 SLPs in phage ELISA and SPR is not entire-
ly clear, but it could be due to the fact that immobilizing the
SLP prevented antibody binding by masking or changing the
conformation of the epitope. Differential epitope presentations
may also account for binding inconsistencies observed for
SLP_VHH26 between phage ELISA/SPR assays and cell
ELISA assay. The remaining VHHs did not bind cells repre-
sentative of 012, 017, 023 or 078 ribotypes. The low frequen-
cy of cross-reactive VHHsmay not be surprising given the low
amino acid identity among SLP LMW subunits from different
ribotypes. We speculate that at least six different epitopes are
being recognized by our pool of VHHs, given that there are
five different specificities inferred from cell binding, motility
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and ELISA/SPR assays, one represented by SLP_VHH2, one
by SLP_VHH5, one by SLP_VHH26 that cross-reacted to 630
strain in phage ELISA/SPR, one by SLP_VHH46 and
SLP_VHH50 that inhibited motility, and one represented by
the remaining VHHs (SLP_VHH12, SLP_VHH22,
SLP_VHH23, and SLP_VHH49). This latter group can be di-
vided into those binding a linear epitope and those binding a
conformational epitope as determined by Western blotting.
Despite their variability, alignment of LMW SLP amino
acid sequences from several C. difficile ribotypes reveal
stretches of conserved residues that could represent epitopes
for cross-reactive antibody binding (Fig. S4). Specifically,
residues 8–11, 72–83, 249–261, 264–275, and 299–321, num-
bered based on the 630 sequence, show significant homology
across all aligned ribotypes (Fagan et al. 2009). Based on
LMW SLP structural data, the LMW SLP is composed of
domain 1 (residues 1–87 and residues 242–248) and domain
2 (residues 97–233), with domain 1 facing toward the bacte-
rial cell wall and the HMW subunit, while domain 2 is orien-
tated away, toward the environment (Fagan et al. 2009). The
residues of domain 2 show the most variability among
ribotypes (Fig. S4) and are also likely the most accessible
for antibody binding given they extend away from the bacte-
rial surface. In the case of the broadly cross-reactive
SLP_VHH5 antibody, it is possible that even though domain
1 of the LMW SLP faces inward toward the cell wall and is in
close proximity to the HMWSLP interaction domain, domain
1 residues remain accessible for binding. Further studies on
this antibody, including co-crystallization structure determina-
tion, could reveal the true nature of the LMWepitope.
Somewhat surprisingly, in agar-stab motility assays, sever-
al VHHs were capable of inhibiting motility of QCD-32g58
cells. In particular, SLP_VHH5 and SLP_VHH46 were capa-
ble of inhibiting motility at both high and low antibody con-
centrations. To a lesser degree, SLP_VHH50was also found to
inhibit motility. Higher affinity, faster kon/slower koff and/or
the nature of epitope of SLP_VHH5 and SLP_VHH46 may
be responsible for their greater motility inhibition potency
compared to SLP_VHH50 (based on Western blot and cell-
binding experiments, SLP_VHH5 and SLP_VHH46 have dif-
ferent epitopes than SLP_VHH50). There are a limited number
of reports of polyclonal antibody and mAb preparations
targeting C. difficile SLPs; however, none have examined
the ability of antibodies to inhibit C. difficile motility.
Takumi et al. (1991) produced anti-SLP Fab fragments and
used them to inhibit the adherence of C. difficile to human
cervical cancer cells and mouse fibroblast cells. O’Brien
et al. (2005) showed that the injection of hamsters with anti-
bodies to SLPs prolonged the survival of C. difficile-infected
hamsters. More recently, anti-HMW SlpA and anti-LMW
SlpA polyclonal antiserum was shown to reduce C. difficile
strain 630 adherence to C2BBE human colonic epithelial cells
although the precise mechanism was not defined (Merrigan
et al. 2013). While our study is unique in that we appear to
inhibit motility through targetingC. difficile SLPs, others have
found motility-inhibiting affinity reagents by targeting an al-
ternative bacterial cell surface structure, namely the lipopoly-
saccharide (LPS). A mAb that bound the LPS of Salmonella
enterica was shown to inhibit flagellum-based motility
(Forbes et al. 2008). Similarly, P22sTsp, a phage tailspike
protein that binds to LPS was also able to inhibit the motility
of Salmonella enterica serovar Typhimurium (Waseh et al.
2010). As would be expected an anti-flagellin mAb inhibited
the motility of multi-drug resistant Pseudomonas aeruginosa
and curbed lethality in mice (Adawi et al. 2012). In another
study, anti-P. aeruginosa flagellin VHHs inhibited the motility
and biofilm formation of P. aeruginosa (Adams et al. 2014).
Similarly an anti-Campylobacter jejuni flagellin VHH
inhibited the motility of C. jejuni (Hussack et al. 2014; Riazi
et al. 2013). To date, there is no known report of SLP interac-
tions with motility factors in C. difficile and SLPs remain the
primary adherence factors of C. difficile. However, the theme
of blocking a surface antigen which is high in abundance,
wherein motility is reduced, is presented in this study and
warrants further investigation. Our data suggests that antibod-
ies binding to C. difficile SLPs may provide some form of
steric hindrance to the effective functioning of the flagellar
motility apparatus. Continued studies on the structure and
function of C. difficile SLPs and their role in host-pathogen
interactions, as well as nature of the LMWepitope recognized
by broadly cross-reactive SLP antibodies which inhibit motil-
ity, will help in elucidating this unusual interaction between
two key surface structures. Whether our SLP-specific VHHs
interfere with cell growth and biofilm formation warrants fur-
ther investigation.
In conclusion, we have isolated a panel of high-affinity
VHHs that target the LMW SLP subunit of C. difficile QCD-
32g58. Many of the VHHs recognized several strains within
the 027 ribotype, which is the predominant hypervirulent
ribotype seen in hospital-acquired (nosocomial) C. difficile
infections. One VHH (SLP_VHH5) additionally recognized
two strains from ribotypes 017 and 078 which are recognized
as emerging PCR ribotypes implicated in recent outbreaks
with increased disease severity (Cheknis et al. 2009; Hunt
and Ballard 2013). Of additional significance, a subset of four
VHHs (SLP_VHH5, SLP_VHH12, SLP_VHH23, and
SLP_VHH46) possessed high affinities, a similar set
(SLP_VHH5, SLP_VHH46, and SLP_VHH50) inhibited mo-
tility and two (SLP_VHH12 and SLP_VHH23) demonstrated
strong resistance to the GI protease pepsin. Affinity matura-
tion combined with a disulfide engineering approach de-
scribed previously (Hussack et al. 2011b; Hussack et al.
2014; Saerens et al. 2008) can be employed to further increase
their affinities, motility inhibition capability and resistance to
GI proteases, making them suitable oral/GI therapeutics
against CDAD or useful agents in the validation of SLP as a
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vaccine target. A combination therapy approach involving the
present anti-SLP VHHs and previously described toxin A- and
toxin B-specific VHHs (Hussack et al. 2011a; Yang et al.
2014) also appears attractive.
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